Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

55
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
55
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

499
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
499
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

75
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
75
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

90
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
90
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

80
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
80
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

69
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Nature communications·2026
Same author

MSR1 Drives MASLD Progression Via Disrupting FoxO3a-SOD3 Mediated Redox Balance in Liver Macrophages.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Retraction Note: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Nature communications·2026
Same author

From Mechanisms to Therapy: Targeting the Gut-Brain Axis in Chronic Gastrointestinal Pain.

Pharmacological research·2026
Same author

Retraction Note: Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance.

Nature communications·2026
Same author

Qi Wei Zhi Gan formulation alleviates progressive fibrosis in metabolic dysfunction-associated steatohepatitis through suppressing Peroxidasin-collagen IV crosslinking.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Related Experiment Video

Updated: Nov 11, 2025

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.2K

Progress on haptoglobin and metabolic diseases.

Bao-Nian Wan1, Shi-Gao Zhou1, Miao Wang1

  • 1Department of TCM Demonstration, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.

World Journal of Diabetes
|March 24, 2021
PubMed
Summary
This summary is machine-generated.

Haptoglobin (Hp) plays a role in various bodily functions and is linked to metabolic diseases like obesity. Further research is needed to clarify its specific mechanisms in these conditions.

Keywords:
CD163HaptoglobinInflammationMetabolic diseasesPolymorphismSimple obesity

More Related Videos

Measurement of Heme Synthesis Levels in Mammalian Cells
09:43

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

12.3K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.4K

Related Experiment Videos

Last Updated: Nov 11, 2025

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases
06:21

Author Spotlight: Investigating Hepatic Adaptations and Prediabetic Progression in Liver Diseases

Published on: October 6, 2023

2.2K
Measurement of Heme Synthesis Levels in Mammalian Cells
09:43

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

12.3K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.4K

Area of Science:

  • Biochemistry
  • Metabolic Disease Research
  • Molecular Biology

Background:

  • Haptoglobin (Hp) is an acidic glycoprotein found in human and mammalian bodily fluids, produced by the liver, adipose tissue, and kidney.
  • Hp exhibits antibacterial, antioxidant, and angiogenic properties and is implicated in diverse diseases, including obesity, diabetes complications, fatty liver disease, hypertension, autoimmune disorders, and cancers.
  • Previous clinical trials indicated altered serum Hp expression in simple obesity patients, but the underlying mechanisms remain unclear.

Purpose of the Study:

  • To review recent advancements in Haptoglobin (Hp) research.
  • To highlight the connection between Hp and the pathogenesis of metabolic diseases.
  • To enhance comprehension of Hp's role in metabolic disorders and suggest future research avenues.

Main Methods:

  • Literature review of recent research on Haptoglobin (Hp).
  • Analysis of studies focusing on Hp's association with metabolic diseases.
  • Synthesis of findings to elucidate Hp's function in metabolic health and disease.

Main Results:

  • Haptoglobin (Hp) is involved in numerous physiological processes.
  • Genetic variations and phenotypes of Hp influence its biological functions.
  • Hp's role in metabolic diseases, particularly simple obesity, warrants further investigation.

Conclusions:

  • Haptoglobin (Hp) is a significant glycoprotein with diverse biological functions.
  • Understanding Hp's mechanisms in metabolic diseases can offer new therapeutic insights.
  • Continued research into Hp is crucial for advancing our knowledge of metabolic health.